POSA236 Real-World Treatment (Tx) Characteristics for Advanced Non-Small Cell Lung Cancer (aNSCLC) Without Actionable Mutations After Introduction of Immune Checkpoint Inhibitors (ICIs) in EU4 and UK
Abstract
Authors
J Multani V Casey S Mpima M Yasuda CC Chen F Manuguid L Kalilani TJ Giove J Chao A Aziez A Stojadinovic C Hogea